Hemophilia A is an inherited condition that results in a deficiency in the factor VIII blood clotting protein. Individuals with hemophilia A are at risk for life-threatening bleeding; bleeding into a joint or muscle is common and can lead to substantial disability. To reduce the risk of bleeding, patients with severe hemophilia A administer factor VIII concentrate intravenously several times per week. About 25% of these patients develop “inhibitors” that make the factor ineffective.

Interventions of Interest:

  • Emicizumab-kxwh (Hemlibra®, Genentech)

For questions, contact info@icer.org.

View the Key Stakeholders List.


Final Documents

Below you will find the final documents from the assessment review process: